MorphoSys

Traded on the St. Petersburg Stock Exchange
MorphoSys is a biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany.The company claims to have more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

MorphoSys balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, €
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

MorphoSys cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

MorphoSys multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

MorphoSys profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
MorphoSys assets
MorphoSys cash flows

MorphoSys dividend policy

The company doesn't provide dividend
MorphoSys news
10.11.2021
MorphoSys' IFRS loss for 9M 2021 was €133.5 million, compared to a profit of €114.4 million in the previous year. Revenue dropped 2.3 times to €126.7 million from €291.7 million a year earlier.
Source: {source} pictogram morphosys.com
Pictogram next
27.08.2021
Incyte and MorphoSys have received conditional marketing authorization from the European Commission for the jointly developed drug Minjuvi in combination with lenalidomide and monotherapy. It is used to treat adults with relapsed or refractory diffuse large B-cell lymphoma.
Source: {source} pictogram morphosys.com
Pictogram next
17.03.2021
MorphoSys net profit under IFRS for 2020 was €97.9 million, compared to a loss of €103 million in the previous year. Revenue increased 4.6 times to €327.7 million from €71.8 million the year before.
Source: {source} pictogram morphosys.com
Pictogram next
11.11.2020
MorphoSys' IFRS net profit for 9 months of 2020 was €114.416 million, against a loss of €52.684 million in the previous year. Revenue increased 4.8 times to €291.654 million, against a loss of €60.678 million a year earlier.
Source: {source} pictogram morphosys.com
Pictogram next
All MorphoSys news
General information
Company nameMorphoSys
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business addressSemmelweisstrasse 7 Planegg, 82152 Germany
Mailing addressSemmelweisstrasse 7 Planegg, 82152 Germany
Websitewww.morphosys.com